Carnitine in the treatment of valproic acid-induced toxicity

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Clinical toxicology

• Publication date

  2008-05-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1080/15563650902752376PMID 19280426
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The measurement of ammonia blood levels in patients taking valproic acid: looking for problems where they do not exist?

  2008cited by this paper
• Severe acute hyperammonemia after brief exposure to valproate.

  2008cited by this paper
• Valproic acid metabolism and its effects on mitochondrial fatty acid oxidation: A review

  2008cited by this paper
• Toxicity of Valproic Acid in Mice with Decreased Plasma and Tissue Carnitine Stores

  2008cited by this paper
• Hepatotoxicity associated with antiepileptic drugs

  2008cited by this paper
• Mitochondrial fatty-acid oxidation disorders.

  2008cited by this paper
• A case of hemoperfusion and L-carnitine management in valproic acid overdose.

  2008cited by this paper
• [Valproate-associated hyperammonemic encephalopathy. Report of one case].

  2007cited by this paper
• Valproate-induced hyperammonaemic encephalopathy: review of 14 cases in the psychiatric setting

  2007cited by this paper
• 2006 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS)

  2007cited by this paper
• Hyperammonemia and valproic acid-induced encephalopathy.

  2007cited by this paper
• Sodium Valproate in the Induction of Unusual Hepatotoxicity

  2007cited by this paper
• Carnitine as an antidote for acute valproate toxicity in children

  2007cited by this paper
• Hyperammonemia due to valproic acid in the psychiatric setting.

  2007cited by this paper
• Two cases of valproic acid poisoning treated with l-carnitine

  2007cited by this paper
• Encefalopatía asociada a Valproato

  2007cited by this paper
• Valproate-associated Hyperammonemic Encephalopathy

  2007cited by this paper
• Valproate‐Induced Hepatic Injury: Analyses of 23 Fatal Cases

  2007cited by this paper
• Valproic Acid–induced Hepatopathy: Nine New Fatalities in Germany from 1994 to 2003

  2006cited by this paper
• Valproate: past, present, and future.

  2006cited by this paper
• Valproate‐induced hyperammonemic encephalopathy

  2006cited by this paper
• Carnitine levels in valproic acid-treated psychiatric patients: a cross-sectional study.

  2005cited by this paper
• Acute Valproate Poisoning: Pharmacokinetics, Alteration in Fatty Acid Metabolism, and Changes During Therapy

  2005cited by this paper
• Science review: Carnitine in the treatment of valproic acid-induced toxicity – what is the evidence?

  2005cited by this paper
• L-carnitine was safely administered in the setting of valproate toxicity.

  2005cited by this paper
• Metabolic viability and pharmaco-toxicological reactivity of cryopreserved human precision-cut renal cortical slices.

  2004cited by this paper
• Comparison of clinical, magnetic resonance and evoked potentials data in a case of valproic-acid-related hyperammonemic coma

  2004cited by this paper
• Épuration extrarénale, supplémentation en L-carnitine et intoxication à l’acide valproïque

  2004cited by this paper
• Intoxications graves par l'acide valproïque

  2004cited by this paper
• [Haemodialysis, L-carnitine therapy and valproic acid overdose].

  2004cited by this paper
• Valproic acid-induced hyperammonemia: a case report.

  2004cited by this paper
• Successful Use of Hemodialysis in Acute Valproic Acid Intoxication

  2004cited by this paper
• Hyperammonemic encephalopathy induced by a combination of valproate and pivmecillinam

  2004cited by this paper
• Carnitine metabolism and deficit--when supplementation is necessary?

  2003cited by this paper
• Effects of Age and Polytherapy, Risk Factors of Valproic Acid (VPA) Hepatotoxicity, on the Excretion of Thiol Conjugates of (E)‐2,4‐diene VPA in People with Epilepsy Taking VPA

  2003cited by this paper
• American Association of Clinical Endocrinologists medical guidelines for the clinical use of dietary supplements and nutraceuticals.

  2003cited by this paper
• Ammonia Induced Encephalopathy from Valproic Acid in a Bipolar Patient: Case Report

  2003cited by this paper
• A case of valproate-associated hepatotoxicity treated with L-carnitine.

  2003cited by this paper
• Carnitine level in Chinese epileptic patients taking sodium valproate.

  2003cited by this paper
• Effect of L-carnitine treatment for valproate-induced hepatotoxicity. Authors' reply

  2002cited by this paper
• Valproic Acid Toxicity: Overview and Management

  2002cited by this paper
• Effect of L-carnitine treatment for valproate-induced hepatotoxicity.

  2002cited by this paper
• Valproate-Induced Hyperammonemic Encephalopathy

  2002cited by this paper
• Valproate-induced hyperammonemia as a cause of altered mental status.

  2002cited by this paper
• Hyperammonemia and coma without hepatic dysfunction induced by valproate therapy.

  2001cited by this paper
• Valproic acid overdose and haemodialysis.

  2001cited by this paper
• Effect of l-carnitine treatment for valproate-induced hepatotoxicity

  2001cited by this paper
• The Role of Carnitine Supplementation during Valproic Acid Therapy

  2000cited by this paper
• Multicenter Case Series of Valproic Acid Ingestion: Serum Concentrations and Toxicity

  2000cited by this paper
• Manual of neurologic therapeutics

  1999cited by this paper
• l‐Carnitine Supplementation in Childhood Epilepsy: Current Perspectives

  1998cited by this paper
• Valproate therapy does not deplete carnitine levels in otherwise healthy children.

  1998cited by this paper
• Carnitine for valproic acid-induced hyperammonemia.

  1997cited by this paper
• Biochemical basis of sodium valproate hepatotoxicity and renal tubular disorder: time dependence of peroxidative injury.

  1997cited by this paper
• Diet- and valproate-induced transient hyperammonemia: effect of L-carnitine.

  1997cited by this paper
• Fatal sodium valproate poisoning.

  1997cited by this paper
• [Hepatic diseases caused by drugs].

  1997cited by this paper
• Successful Treatment by Direct Hemoperfusion of Coma Possibly Resulting From Mitochondria1 Dysfunction in Acute Valproate Intoxication

  1997cited by this paper
• Asymptomatic Hyperammonemia in Children Treated With Valproic Acid

  1997cited by this paper
• Valproate induced encephalopathy treated with carnitine in an adult.

  1996cited by this paper
• Valproic acid overdose and L-carnitine therapy.

  1996cited by this paper
• The effect of carnitine supplementation in valproate‐induced hyperammonaemia

  1996cited by this paper
• Effect of L‐Carnitine Supplementation on Acute Valproate Intoxication

  1996cited by this paper
• Inhibition of carnitine biosynthesis by valproic acid in rats--the biochemical mechanism of inhibition.

  1996cited by this paper
• Valproate Metabolites in High‐Dose Valproate Plus Phenytoin Therapy

  1996cited by this paper
• [Acute hepatic failure associated with valproic acid in children. Report of 3 cases].

  1996cited by this paper
• Valproic acid hepatic fatalities. III. U.S. experience since 1986

  1996cited by this paper
• Delayed peak serum valproic acid in massive divalproex overdose--treatment with charcoal hemoperfusion.

  1996cited by this paper
• Fluorinated analogues as mechanistic probes in valproic acid hepatotoxicity: hepatic microvesicular steatosis and glutathione status.

  1995cited by this paper
• Life threatening intoxication with sodium valproate.

  1995cited by this paper
• Plasma and hepatic carnitine and coenzyme A pools in a patient with fatal, valproate induced hepatotoxicity.

  1995cited by this paper
• Valproate Increases Glutaminase and Decreases Glutamine Synthetase Activities in Primary Cultures of Rat Brain Astrocytes

  1994cited by this paper
• Severe Hepatotoxicity During Valproate Therapy: An Update and Report of Eight New Fatalities

  1994cited by this paper
• Reversal of valproic acid-associated impairment of carnitine uptake in cultured human skin fibroblasts.

  1994cited by this paper
• Valproate (VPA) Metabolites in Various Clinical Conditions of Probable VPA‐Associated Hepatotoxicity

  1993cited by this paper
• Unusual electronmicroscopic changes in valproate-associated liver failure.

  1993cited by this paper
• Reversal of the Adverse Chronic Effects of the Unsaturated Derivative of Valproic Acid—2-n-Propyl-4-Pentenoic Acid—on Ketogenesis and Liver Coenzyme A Metabolism by a Single Injection of Pantothenate, Carnitine, and Acetylcysteine in Developing Mice

  1993cited by this paper
• Hepatotoxic effects in a child receiving valproate and carnitine.

  1993cited by this paper
• Cerebral edema following acute sodium valproate overdose.

  1992cited by this paper
• Review Article: Carnitine, Valproate, and Toxicity

  1991cited by this paper
• Carnitine, valproate, and toxicity.

  1991cited by this paper
• Muscle carnitine deficiency in patients using valproic acid.

  1991cited by this paper
• Alteration of renal carnitine metabolism by anticonvulsant treatment

  1991cited by this paper
• Valproic acid hepatic fatalities.

  1989cited by this paper
• Hepatic and renal contributions to valproic acid‐induced hyperammonemia

  1988cited by this paper
• Valproate Metabolites and Hepatotoxicity in an Epileptic Population

  1988cited by this paper
• Hepatotoxicity in Rat Following Administration of Valproic Acid: Effect of L‐Carnitine Supplementation

  1987cited by this paper
• Nutritional Influence on Serum Ammonia in Young Patients Receiving Sodium Valproate

  1986cited by this paper
• Carnitine status in Reye and Reye-like syndromes.

  1986cited by this paper
• Serum Carnitine During Valproic Acid Therapy

  1986cited by this paper
• Carnitine as an essential nutrient.

  1986cited by this paper
• Valproylcarnitine: a novel drug metabolite identified by fast atom bombardment and thermospray liquid chromatography-mass spectrometry.

  1985cited by this paper
• Valproate: an updated review

  1985cited by this paper
• Valproic acid associated abnormalities of carnitine metabolism.

  1985cited by this paper
• Drugs effective in the therapy of the epilepsies

  1985cited by this paper
• Dicarboxylic acids and the lipid metabolism.

  1984cited by this paper
• Carnitine deficiency: a possible mechanism for valproate hepatotoxicity.

  1984cited by this paper
• Dicarboxylic acids and the lipid metabolism.

  1984cited by this paper
• The Hepatotoxicity of Valproic Acid and Its Metabolites in Rats. I. Toxicologic, Biochemical and Histopathologic Studies

  1984cited by this paper
• The renal origin of sodium valproate‐induced hyperammonemia in fasting humans

  1983cited by this paper

• Valproic Acid and Famotidine Drug-Drug Interaction: Report of a Pediatric Case

  2026cites this paper
• In vitro assay of pharmacobezoar formation with extended-release divalproex sodium tablets.

  2026cites this paper
• In vitro assay of pharmacobezoar formation with extended-release divalproex sodium tablets.

  2025cites this paper
• Antidotes

  2025cites this paper
• Advancements in Valproate Therapy for Seizures, Migraines, and Bipolar Disorders

  2025cites this paper
• Intentional use of ertapenem to reduce valproic acid concentrations in overdose: two case reports

  2025cites this paper
• Mitochondrial dysfunction in drug-induced hepatic steatosis: recent findings and current concept.

  2025cites this paper
• Trends in antidote use in France from 2015 to 2021: a nationwide poison centers study

  2025cites this paper
• Antidoti

  2025cites this paper
• Effect of L-Carnitine on Muscle Quality and Antioxidant Capacity of Hybrid Sheep at an Early Stage

  2025cites this paper
• Why Physicians Delay in the Diagnosis and Treatment of Valproic Acid Toxicity

  2025cites this paper
• A precision approach to therapeutic drug monitoring of valproate to evaluate markers of toxicity

  2025cites this paper
• Anfallssuppressive medikamentöse Langzeittherapie: Problemerkennung und Problembeseitigung

  2025cites this paper
• Risk Factors and Multiple Interaction Effects for Hyperammonemia in Patients Receiving Valproic Acid

  2025cites this paper
• Research Progress on the Etiology of Cholestatic Liver Disease in School-Age Children

  2025cites this paper
• Pexidartinib impairs liver mitochondrial functions causing cell death in primary human hepatocytes at clinically relevant concentrations.

  2025cites this paper
• Association of dietary vitamin K1 intake with epilepsy in adults in US: a cross-sectional study of National Health and Nutrition Examination Survey 2013–2018

  2024cites this paper
• Valproate-Induced Hyperammonemic Encephalopathy Successfully Treated With Levocarnitine in an Elderly Patient Without Liver Dysfunction

  2024cites this paper
• L‐carnitine for valproic acid‐induced toxicity

  2024influential citation
• Valproate encephalopathy: Case series and literature review

  2024cites this paper
• The role of SIRT1-FXR signaling pathway in valproic acid induced liver injury: a quantitative targeted metabolomic evaluation in epileptic children

  2024cites this paper
• Drug-induced liver injury in children

  2024cites this paper
• The Mendelian disorders of chromatin machinery: Harnessing metabolic pathways and therapies for treatment.

  2024cites this paper
• Substitution of One Meat-Based Meal With Vegetarian and Vegan Alternatives Generates Lower Ammonia and Alters Metabolites in Cirrhosis: A Randomized Clinical Trial

  2024cites this paper
• Carbapenems as Antidotes for the Management of Acute Valproic Acid Poisoning

  2024cites this paper
• A Rare Case Report of Hypoketotic Hypoglycemia Induced Seizures Due to Secondary Carnitine Deficiency in a 44-year-old Female

  2024cites this paper
• Valproate, risperidone, and paliperidone: A case of valproate-induced hyperammonemic encephalopathy

  2024cites this paper
• Hyperammonemic encephalopathy induced by valproic acid

  2024cites this paper
• Five-day administration of ivermectin is effective in attenuating valproic acid-induced liver toxicity in rats

  2024cites this paper
• Etiology and Diagnosis and Treatment of Markedly Elevated Transaminases

  2023cites this paper
• EFFECT OF BITTER MELON AGAINST CISPLATIN AND VALPROIC ACID-INDUCED GENOTOXICITY IN Drosophila melanogaster Meigen

  2023cites this paper
• Challenges in the Clinical Diagnosis of Lithium Toxicity: A Case Report

  2023cites this paper
• Carnitine metabolites and cognitive improvement in patients with schizophrenia treated with olanzapine: a prospective longitudinal study

  2023cites this paper
• Carnitine in Alleviation of Complications Caused by Acute Valproic Acid Toxicity; an Exprimental Study on Mice

  2023cites this paper
• Pharmacogenetics-Informed Pharmacometabolomics as an Innovative Approach to Assessing the Safety and Risk of Pharmacotherapy with Valproic Acid

  2023cites this paper
• Valproate induced hyperammonemic encephalopathy: a rare adverse effect of a common drug

  2023cites this paper
• Valproic Acid–Associated Hyperammonemia

  2023cites this paper
• Antidotes

  2023cites this paper
• Therapeutic and Toxic Effects of Valproic Acid Metabolites

  2023cites this paper
• Valproate-Induced Encephalopathy Presenting at Therapeutic Blood Concentrations: A Case Report and Literature Review

  2023cites this paper
• Carnitine Deficiency after Long-Term Continuous Renal Replacement Therapy

  2022cites this paper
• Metabolomic profiling of triple negative breast cancer cells suggests that valproic acid can enhance the anticancer effect of cisplatin

  2022influential citation
• Targeting the epigenome in malignant melanoma: Facts, challenges and therapeutic promises.

  2022cites this paper
• Valproic Acid Overdose: Case Report and Literature Review.

  2022cites this paper
• The serum acylcarnitines profile in epileptic children treated with valproic acid and the protective roles of peroxisome proliferator-activated receptor a activation in valproic acid-induced liver injury

  2022cites this paper
• Determination of valproic acid and its six metabolites in human serum by LC-MS/MS and application to interaction with carbapenems in epileptic patients.

  2022cites this paper
• N-Acetylcysteine for the Management of Non-Acetaminophen Drug-Induced Liver Injury in Adults: A Systematic Review

  2022cites this paper
• Protective effects of L-carnitine against valproic acid-induced memory impairment and anxiety-like behavior in adult rat.

  2022cites this paper
• Case Report: A Case of Valproic Acid-Induced Hyperammonemic Encephalopathy Associated With the Initiation of Lithium: A Re-duplicable Finding

  2022cites this paper
• Therapeutic Management of Idiosyncratic Drug-Induced Liver Injury and Acetaminophen Hepatotoxicity in the Paediatric Population: A Systematic Review

  2022cites this paper
• The Role of l-Carnitine in Mitochondria, Prevention of Metabolic Inflexibility and Disease Initiation

  2022cites this paper
• The effect of sodium benzoate, L-carnitine, and phenylacetate on valproate-induced hyperammonemia in Male Wistar rats.

  2022cites this paper
• Undifferentiated non-hepatic hyperammonemia in the ICU: Diagnosis and management.

  2022cites this paper
• L-carnitine does not improve valproic acid poisoning management: a cohort study with toxicokinetics and concentration/effect relationships

  2022cites this paper
• Novel Therapies for the Treatment of Drug-Induced Liver Injury: A Systematic Review

  2022cites this paper
• Examination of the emerging role of transporters in the assessment of nephrotoxicity

  2022cites this paper
• Embryonic Hypotaurine Levels Contribute to Strain-Dependent Susceptibility in Mouse Models of Valproate-Induced Neural Tube Defects

  2022influential citation
• Long-Term Effects of Antiseizure Medications

  2022cites this paper
• Non‐hyperammonaemia valproate‐induced encephalopathy: A case report

  2021cites this paper
• Rapid Rescue From Hyperammonemic Coma After Valproic Acid Poisoning: Dual Therapy With Continuous Renal Replacement Therapy and L-Carnitine Supplementation

  2021cites this paper
• The role of efflux transporters and metabolizing enzymes in brain and peripheral organs to explain drug‐resistant epilepsy

  2021cites this paper
• Drug- or toxin-induced mitochondrial toxicity

  2021cites this paper
• Dihydrolipoamide dehydrogenase, pyruvate oxidation, and acetylation-dependent mechanisms intersecting drug iatrogenesis

  2021cites this paper
• Hyperammonemia during treatment with valproate in critically ill patients.

  2021cites this paper
• Role of Carnitine in Non-alcoholic Fatty Liver Disease and Other Related Diseases: An Update

  2021cites this paper
• Method of Preparing Blood Samples on Solid Sorbents for Quantitative Determination of Valproic Acid with Gas Chromatography and Mass Spectrometric Detection

  2021cites this paper
• L-Carnitine and Acylcarnitines: Mitochondrial Biomarkers for Precision Medicine

  2021cites this paper
• Relevante Aspekte der arzneimittelassoziierten Hepatotoxizität im klinischen Alltag

  2021cites this paper
• Drug-induced liver injury: Asia Pacific Association of Study of Liver consensus guidelines

  2021cites this paper
• The Cerebral Effect of Ammonia in Brain Aging: Blood–Brain Barrier Breakdown, Mitochondrial Dysfunction, and Neuroinflammation

  2021cites this paper
• Effects of l-carnitine supplementation in patients with childhood-onset epilepsy prescribed valproate.

  2021cites this paper
• Research Progress on the Effect of Epilepsy and Antiseizure Medications on PCOS Through HPO Axis

  2021cites this paper
• Non-Hepatic Hyperammonemia: A Potential Therapeutic Target for Sepsis-Associated Encephalopathy.

  2021cites this paper
• Drug induced liver injury: an update

  2020cites this paper
• Butyrate prevents valproate‐induced liver injury: In vitro and in vivo evidence

  2020cites this paper
• Waddling Gait

  2020cites this paper
• Prevention and management of idiosyncratic drug-induced liver injury: Systematic review and meta-analysis of randomised clinical trials.

  2020cites this paper
• Selenium and L-carnitine protects from valproic acid-Induced oxidative stress and mitochondrial damages in rat cortical neurons

  2020cites this paper
• Thinking out of the box: management of valproic acid toxicity with carbapenems

  2020cites this paper
• Frequent Offenders and Patterns of Injury.

  2020cites this paper
• Valproic acid up-regulates the whole NO-citrulline cycle for potent iNOS-NO signaling to promote neuronal differentiation of adipose tissue-derived stem cells.

  2020cites this paper
• Valproic acid promotes mitochondrial dysfunction in primary human hepatocytes in vitro; impact of C/EBPα-controlled gene expression

  2020cites this paper
• Drug‐Induced Liver Injury in GI Practice

  2020cites this paper
• Influence of Low Carbohydrate High Fat Ketogenic Diets on Renal and Liver Parameters

  2020cites this paper
• EASL Clinical Practice Guidelines: Drug-induced liver injury

  2019cites this paper
• Endoplasmic Reticulum Stress-induced Upregulation of STARD1 Promotes Acetaminophen-induced Acute Liver Failure.

  2019influential citation
• Drug-induced liver injury

  2019cites this paper
• Status epilepticus in mitochondrial diseases and the role of POLG1 variants in the valproic-acid induced hepatotoxicity

  2019cites this paper
• Potential biomarker of fibroblast growth factor 21 in valproic acid-treated livers.

  2019cites this paper
• Efficacy and Safety of Valproic Acid for Spinal Muscular Atrophy: A Systematic Review and Meta-Analysis

  2019cites this paper
• Valproic Acid and the Liver Injury in Patients with Epilepsy: An Update.

  2019cites this paper
• Rhabdomyolysis and Hepatotoxicity From Valproic Acid: Case Reports

  2019cites this paper
• EASL Clinical Practice Guidelines: Drug-induced liver injury.

  2019cites this paper
• Carnitine Inborn Errors of Metabolism

  2019cites this paper
• L-Carnitine Treatment In Acute Valproic Acid Intoxication: Case Report

  2019influential citation
• Characterizing acyl-carnitine biosignatures for schizophrenia: a longitudinal pre- and post-treatment study

  2019cites this paper
• Musanga cecropioides (Urticaceae) stem-bark mitigates sodium valproate –induced pantoxicity derangement in albino rats

  2019influential citation
• Systemic Metabolomic Profiling of Acute Myeloid Leukemia Patients before and During Disease-Stabilizing Treatment Based on All-Trans Retinoic Acid, Valproic Acid, and Low-Dose Chemotherapy

  2019cites this paper
• Hyperammonemic Encephalopathy and Lipid Dysmetabolism in a Critically Ill Patient After a Short Course of Amiodarone

  2019cites this paper
• Antiepileptic drugs: Role in paediatric poisoning

  2018cites this paper